cvs yeztugo - Search News

News

CVS, HIV and Yeztugo

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.

Yahoo · 11h

CVS Health denies coverage for breakthrough HIV drug, committing 'clear violation' of ACA

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory factors."

Fierce Healthcare · 1d

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention breakthrough, at least for now. | CVS Health, the parent of PBM juggernaut CVS Caremark,

1don MSN

Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

STAT1d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Josh Nathan-Kazis is a senior writer at Barron's, covering the healthcare industry. He is a former staff writer at the Forward, where he investigated nonprofits, covered local and national politics, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results